Compare · QURE vs RGNX
QURE vs RGNX
Side-by-side comparison of uniQure N.V. (QURE) and REGENXBIO Inc. (RGNX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. QURE focuses on Biotechnology: Pharmaceutical Preparations, while RGNX focuses on Biotechnology: Biological Products (No Diagnostic Substances).
- QURE is the larger of the two at $3.09B, about 6.0x RGNX ($514.4M).
- Over the past year, QURE is up 245.7% and RGNX is up 16.1% - QURE leads by 229.6 points.
- QURE has been more active in the news (31 items in the past 4 weeks vs 13 for RGNX).
- QURE has more recent analyst coverage (23 ratings vs 22 for RGNX).
- Company
- uniQure N.V.
- REGENXBIO Inc.
- Price
- $49.13+10.70%
- $9.94+9.53%
- Market cap
- $3.09B
- $514.4M
- 1M return
- +98.26%
- +47.04%
- 1Y return
- +245.74%
- +16.12%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2014
- 2015
- News (4w)
- 31
- 13
- Recent ratings
- 23
- 22
uniQure N.V.
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-180 for the treatment of hemophilia A; AMT-190, an IV-administered adeno-associated virus (AAV) 5-based gene therapy for the treatment of Fabry disease; and AMT-150, a one-time, intrathecally-administered, AAV gene therapy for treating spinocerebellar ataxia type 3. The company has collaboration and license agreements with Bristol Myers-Squibb Company; Gen-X; and Synpromics Limited. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
REGENXBIO Inc.
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase I/IIa clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II; RGX-111, which is in Phase I clinical trial for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease; and RGX-501, which is in Phase I/II clinical trials to treat homozygous familial hypercholesterolemia. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop vectorized antibodies for the treatment of neurodegenerative diseases. The company was formerly known as ReGenX Biosciences, LLC and changed its name to REGENXBIO Inc. in September 2014. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
Latest QURE
- uniQure Announces Pricing of Upsized $225 Million Public Offering
- uniQure Announces $150 Million Proposed Public Offering
- SEC Form 424B5 filed by uniQure N.V.
- CEO, Managing Director Kapusta Matthew C exercised 67,237 units of Ordinary Shares at a strike of $20.24 and sold $9,371,612 worth of Ordinary Shares (206,100 units at $45.47) as part of a pre-agreed trading plan, decreasing direct ownership by 21% to 521,795 units (SEC Form 4)
- Director Balachandran Madhavan exercised 11,685 units of Ordinary Shares at a strike of $24.97 and sold $526,485 worth of Ordinary Shares (11,685 units at $45.06) as part of a pre-agreed trading plan (SEC Form 4)
- Director Kaye Jack exercised 5,295 units of Ordinary Shares at a strike of $31.71 and sold $225,408 worth of Ordinary Shares (5,295 units at $42.57) as part of a pre-agreed trading plan (SEC Form 4)
- uniQure N.V. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- uniQure Announces Preliminary Data on the First Cohort in the Phase I/IIa Clinical Trial of AMT-260 in Refractory Mesial Temporal Lobe Epilepsy
- SEC Form 144 filed by uniQure N.V.
- uniQure upgraded by Barclays with a new price target
Latest RGNX
- REGENXBIO Announces Alignment with FDA on Path Forward for NAVSUNLI™ BLA Resubmission for Accelerated Approval; First Potential Gene Therapy for MPS II
- Amendment: SEC Form SCHEDULE 13G/A filed by REGENXBIO Inc.
- SEC Form SC TO-I filed by REGENXBIO Inc.
- REGENXBIO Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events
- Director Tasse Daniel was granted 9,807 shares, increasing direct ownership by 51% to 28,861 units (SEC Form 4)
- Director Stump David C was granted 9,807 shares, increasing direct ownership by 51% to 28,861 units (SEC Form 4)
- Director Zachary Jennifer was granted 9,807 shares, increasing direct ownership by 44% to 31,871 units (SEC Form 4)
- Director Mills Kenneth T. was granted 9,807 shares, increasing direct ownership by 2% to 495,925 units (SEC Form 4)
- Director Migausky George V was granted 9,807 shares, increasing direct ownership by 51% to 28,861 units (SEC Form 4)
- Director Karabelas Argeris N was granted 9,807 shares, increasing direct ownership by 51% to 28,861 units (SEC Form 4)